Our CEO, Francois Salmon, was at the MedTech Strategist in Dublin to demonstrate Anaconda Biomed's dedication to finding a safe and efficient way to perform a mechanical thrombectomy. A big thank you to everyone involved and to all those who support our project 🐍 Innogest Capital Ysios Capital Omega Funds Asabys Partners #MedTechStrategist #MedTechInnovation
Now presenting at #InnovationDublin24 is Anaconda BioMed with CEO Francois Salmon Remain informed on new articles, conference updates and more with our helpful medtech community newsletter. Subscribe here: https://bit.ly/42KHJKI The ANA5 system from Anaconda Biomed (Sant Quirze -Barcelona- Spain) is intended to be inserted and navigated to the neurovascular anatomy. The funnel is deployed by retracting the conduit catheter and is intended, when deployed, to provide temporary vascular flow restriction. The device is indicated for restoring blood flow in patients experiencing an acute ischemic stroke due to large vessel occlusion. Anaconda Biomed aims to increase penetration of mechanical thrombectomy for stroke by optimizing its device to achieve the benefits of “The First Pass Effect.
Thank you Anaconda BioMed for sharing and many thank yous to Francois Salmon for joining us at #InnovationDublin24!